{ "ok": true, "cik": "1623526", "ticker": "STOK", "name": "Stoke Therapeutics, Inc.", "filings": [ { "form": "8-K", "filed": "2026-09-25", "items": [ "5.02 Departure or Election of Directors; Appointment of Officers" ], "url": "https://www.sec.gov/Archives/edgar/data/1623526/000119312526402820/0001193125-26-402820-index.htm" }, { "form": "8-K", "filed": "2026-08-03", "items": [ "8.01 Other Events", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1623526/000119312526330804/0001193125-26-330804-index.htm" }, { "form": "10-Q", "filed": "2026-08-03", "items": [], "url": "https://www.sec.gov/Archives/edgar/data/1623526/000119312526330557/0001193125-26-330557-index.htm" }, { "form": "8-K", "filed": "2026-08-03", "items": [ "2.02 Results of Operations and Financial Condition", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1623526/000119312526330537/0001193125-26-330537-index.htm" }, { "form": "8-K", "filed": "2026-06-30", "items": [ "7.01 Regulation FD Disclosure", "8.01 Other Events", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1623526/000119312526289409/0001193125-26-289409-index.htm" }, { "form": "8-K", "filed": "2026-06-04", "items": [ "5.07 Submission of Matters to a Vote of Security Holders" ], "url": "https://www.sec.gov/Archives/edgar/data/1623526/000119312526257394/0001193125-26-257394-index.htm" } ], "events12m": 14, "healthWatch": { "window": "last 12 months", "since": "2025-09-28", "signals": [ { "code": "4.01", "label": "Auditor change", "count": 1, "latest": { "filed": "2026-03-27", "url": "https://www.sec.gov/Archives/edgar/data/1623526/000119312526129168/0001193125-26-129168-index.htm" } }, { "code": "5.02", "label": "Director or officer change", "count": 4, "latest": { "filed": "2026-09-25", "url": "https://www.sec.gov/Archives/edgar/data/1623526/000119312526402820/0001193125-26-402820-index.htm" } } ], "note": "Events the company itself filed with the SEC, most serious first. Shown beside the figures; they do not change the range or its receipt." }, "sources": { "facts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0001623526.json", "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1623526" }, "license": "Figures as filed with the SEC. Card text CC BY 4.0, POPS4.", "notAdvice": "Reporting, not investment advice. No price targets and no trading recommendations.", "edgar": "🫧 Edgar looked up Stoke Therapeutics, Inc. ($STOK). Last filing: 8-K (5.02 Departure or Election of Directors; Appointment of Officers), 2026-09-25. 14 event filings (8-K) in the past twelve months. Auditor change (8-K Item 4.01) filed 2026-03-27.", "auditor": { "changes": [ { "filed": "2026-03-27", "url": "https://www.sec.gov/Archives/edgar/data/1623526/000119312526129168/0001193125-26-129168-index.htm" } ], "nonReliance": [], "restatedSince": null }, "metrics": { "fiscalYearEnd": "2025-12-31", "revenue": 184420000, "revenueGrowth1y": 4.045000683900971, "revenueGrowthPerYear": 1.4583740051477623, "yearsOfData": 4, "operatingMargin": -0.11164732675414814, "operatingMarginPrior": -2.773136369853645, "netMargin": -0.037333261034594944, "operatingCashFlow": 45585000, "capitalSpending": 670000, "freeCashFlow": 44915000, "researchAndDevelopment": 137922000, "researchShareOfRevenue": 0.7478689946860427, "cash": 84220000, "longTermDebt": null, "longTermDebtChange": null, "revenueHistory": [ { "fiscalYearEnd": "2022-12-31", "revenue": 12405000 }, { "fiscalYearEnd": "2023-12-31", "revenue": 8780000 }, { "fiscalYearEnd": "2024-12-31", "revenue": 36555000 }, { "fiscalYearEnd": "2025-12-31", "revenue": 184420000 } ], "totalEquity": 352457000, "totalAssets": 418434000, "equityRatio": 0.8423239985278443, "returnOnEquity": -0.01953429780086649, "dividendsPaid": null, "payoutRatio": null, "dividendPerShare": null, "dividendYearsRising": null, "dividendCut": null, "priceBased": "Dividend yield, price/earnings and price/book need a share price. The boards carry filings only, so they are not shown.", "earningsPerShare": -0.12, "sharesOutstanding": 59219184, "bookValuePerShare": 5.951736856083664, "revenuePerShare": 3.1141935356623622, "range80": { "low": 573747326.0127426, "high": 802223350.4166983, "baseline": 691932706.5698483, "n": 4309, "band": "b01", "bandLabel": "$100M–1B", "method": "v4.1", "credibility": 0, "growthYears": 1, "ownVolatility": null, "classVolatility": 0.1022985825903761, "volatility": 0.1022985825903761 }, "ifPaceHeld": { "low": 573747326.0127426, "high": 802223350.4166983 } }, "edgarette": "🔖 Exposure: revenue $184.4M (FY2025). Experience: revenue up 404.5% on the year, up 145.8% a year over 3 years; operating margin -11.2%, up from -277.3%. Soundness: equity 84.2% of assets, return on equity -2.0%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $573.7M and $802.2M next year (method v4.1: its own 1-year record of growth weighed at 0% against $100M–1B filers; on a year the method never saw, 83.4% landed inside). In a shock year the stress range is $527.1M to $876.2M. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -11.2% against a -3.8% median; growth 404.5% against 13.7%.", "peers": { "sic": 2834, "sicDescription": "Pharmaceutical Preparations", "calendarYear": 2025, "minRevenue": 50000000, "depth": 4, "group": "2834", "growth": [ 0.1365, 111 ], "opMargin": [ -0.038, 114 ], "equityRatio": [ 0.4028, 118 ], "returnOnEquity": [ -0.0112, 100 ], "payoutRatio": [ 0.403, 13 ] }, "summary": "Stoke Therapeutics (STOK) grew revenue 405% in FY2025 to $184 million, operating margin -11.2% against a -3.8% median for pharmaceutical preparations, equity 84.2% of assets. Every figure is from the company’s own annual report filed with the SEC.", "chart": "
Stoke Therapeutics, Inc. against its own record and its peers
Operating marginPeer median -3.8%-11.2%Revenue, on the yearPeer median 13.7%404.5%Equity of assetsPeer median 40.3%84.2%Return on equityPeer median -1.1%-2.0%Gold tick: the median of 100–118 peers with $50M+ revenue in pharmaceutical preparations
", "chartHorizon": null, "backtest": { "tests": 0, "hits": 0, "rate": null, "method": "v4", "byYear": {}, "note": "hindsight: the same credibility-weighted range on the company's own past years. Years 2018-2023 were used to fit or tune the method, so only 2025 outcomes are fully out of sample." }, "registry": { "logged": "2026-09-28T14:33:57.029Z", "hash": "82428c7c5055f87f", "status": "open" }, "caution": "Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.", "schema": "pops4.edgarette.card/1", "card": { "summary": "Stoke Therapeutics (STOK) grew revenue 405% in FY2025 to $184 million, operating margin -11.2% against a -3.8% median for pharmaceutical preparations, equity 84.2% of assets. Every figure is from the company’s own annual report filed with the SEC.", "exposure": { "fiscalYearEnd": "2025-12-31", "revenue": 184420000, "totalDebt": null, "cash": 84220000 }, "experience": { "revenueGrowth1y": 4.045000683900971, "revenueGrowthPerYear": 1.4583740051477623, "operatingMargin": -0.11164732675414814, "operatingMarginPrior": -2.773136369853645, "netMargin": -0.037333261034594944, "freeCashFlow": 44915000 }, "soundness": { "equityRatio": 0.8423239985278443, "returnOnEquity": -0.01953429780086649, "payoutRatio": null, "dividendPerShare": null, "dividendYearsRising": null, "dividendCut": null, "note": "Dividend yield, price/earnings and price/book need a share price. The boards carry filings only, so they are not shown." }, "peers": { "sic": 2834, "sicDescription": "Pharmaceutical Preparations", "calendarYear": 2025, "minRevenue": 50000000, "depth": 4, "group": "2834", "growth": [ 0.1365, 111 ], "opMargin": [ -0.038, 114 ], "equityRatio": [ 0.4028, 118 ], "returnOnEquity": [ -0.0112, 100 ], "payoutRatio": [ 0.403, 13 ] }, "credibility": { "auditedYears": 4, "weight": "reasonable", "standard": "ASOP No. 25", "nonReliance": null, "auditorChange": { "filed": "2026-03-27", "url": "https://www.sec.gov/Archives/edgar/data/1623526/000119312526129168/0001193125-26-129168-index.htm" } }, "healthWatch": { "window": "last 12 months", "since": "2025-09-28", "signals": [ { "code": "4.01", "label": "Auditor change", "count": 1, "latest": { "filed": "2026-03-27", "url": "https://www.sec.gov/Archives/edgar/data/1623526/000119312526129168/0001193125-26-129168-index.htm" } }, { "code": "5.02", "label": "Director or officer change", "count": 4, "latest": { "filed": "2026-09-25", "url": "https://www.sec.gov/Archives/edgar/data/1623526/000119312526402820/0001193125-26-402820-index.htm" } } ], "note": "Events the company itself filed with the SEC, most serious first. Shown beside the figures; they do not change the range or its receipt." }, "range": { "low": 573747326.0127426, "high": 802223350.4166983, "baseline": 691932706.5698483, "coverage": 0.8, "method": "v4.1", "basis": "next fiscal year revenue: baseline = revenue x (1 + mean of one-year and three-year pace); width = the company's own volatility of yearly growth, credibility-weighted against its size class (Buhlmann), scaled to the 80% target on 2023 and tested on 2024", "calibratedOn": { "companyYears": 4309, "sizeBand": "$100M–1B", "fitYears": [ 2018, 2022 ], "tuneYear": 2023, "testYear": 2024, "coverageOnTestYear": 0.8341 }, "credibility": { "weightOnOwnRecord": 0, "growthYears": 1, "ownVolatility": null, "classVolatility": 0.1022985825903761, "pricedVolatility": 0.1022985825903761, "k": 3 }, "stress": { "low": 527099483.8173883, "high": 876198499.9501536, "basis": "the same range with widths set to hold 80% across 2018-2023, pandemic years included" }, "kind": "a statistical range, not company guidance; no view on the share price", "track": { "backtest": { "tests": 0, "hits": 0, "rate": null, "method": "v4", "byYear": {}, "note": "hindsight: the same credibility-weighted range on the company's own past years. Years 2018-2023 were used to fit or tune the method, so only 2025 outcomes are fully out of sample." }, "registry": { "logged": "2026-09-28T14:33:57.029Z", "hash": "82428c7c5055f87f", "status": "open" }, "scorecard": "https://www.pops4.com/boards/scorecard" } }, "caution": "Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.", "sources": { "facts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0001623526.json", "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1623526" }, "speedCash": { "fiscalYear": 2025, "cashConversion": 0.2472, "growth3y": 1.4589, "volatility": null, "paysDividend": false, "raisedDividend": false, "equityRatio": 0.8423, "quadrant": null, "compass": null, "band": "$100M-1B", "cashPctInClass": 77, "growthPctInClass": 98, "source": "SEC XBRL frames, the company’s own audited figures; quadrant split at the median of its size class" }, "harbor": { "signs": [ { "key": "warning", "text": "filed auditor change in the last 12 months" } ], "rule": "Boat condition = number of warning signs: a serious warning filing in 12 months; liabilities over assets; slow and jumpy; negative operating cash; an 80% revenue range of ±25% or wider.", "level": 1, "name": "Sound ship", "plain": "one warning sign" }, "cashFlow": { "fiscalYearEnd": "2025-12-31", "operating": 45585000, "investing": -186812000, "financing": 97389000, "capitalSpending": 670000, "free": 44915000, "trend": [ { "fiscalYearEnd": "2022-12-31", "operating": -31866000, "free": -35828000 }, { "fiscalYearEnd": "2023-12-31", "operating": -81067000, "free": -82683000 }, { "fiscalYearEnd": "2024-12-31", "operating": -86851000, "free": -87054000 }, { "fiscalYearEnd": "2025-12-31", "operating": 45585000, "free": 44915000 } ], "note": "Annual, as filed in 10-K cash flow statements; negative investing/financing = cash going out (capital spending, buybacks, dividends, debt repaid)." }, "investments": { "fiscalYearEnd": "2025-12-31", "cash": 84220000, "shortTerm": 200450000, "longTerm": 106260000, "equityHoldings": null, "totalAssets": 418434000, "ladder": null, "currentRatio": 5.28, "unrealizedGain": 555000, "unrealizedLoss": 10000, "note": "Balance-sheet cash and investment securities at fiscal year end, as filed; short-term = due or saleable within a year. Insurers and banks hold most of their book here." } }, "definitions": { "operatingMargin": "Operating income divided by revenue.", "netMargin": "Net income divided by revenue.", "freeCashFlow": "Cash from operations minus spending on property and equipment.", "researchShareOfRevenue": "Research and development expense for the year as a share of revenue, both as filed.", "equityRatio": "Shareholders equity as a share of total assets, both as filed. Higher means less of the company is owed to someone else.", "returnOnEquity": "Net income for the year against shareholders equity at year end.", "payoutRatio": "Dividends paid as a share of net income, in the year the cash went out.", "dividendYearsRising": "Consecutive years, counted back from the last on record, in which dividend per share rose. A fall ends the run and is reported as dividendCut.", "revenueGrowthPerYear": "Compound annual growth between the first and latest fiscal years shown.", "credibility": "How much weight a record deserves, in the actuarial sense (ASOP No. 25): more audited years, more weight.", "peers": "Medians of SEC filers with $50M+ revenue in the same industry code (SIC), narrowest group with at least 8 filers, calendar-year figures from SEC XBRL frames.", "backtest": "The same range method applied to the company's own past years, scored against what it actually reported next. Hindsight, and labelled so.", "healthWatch": "Distress-type events the company filed in the last 12 months (late-filing notices; 8-K items 1.03, 3.01, 2.04, 4.02, 4.01, 2.05, 2.06, 1.05, 5.02), each with its count and newest filing. Display only: they do not change the range or its receipt." }, "speedCash": { "fiscalYear": 2025, "cashConversion": 0.2472, "growth3y": 1.4589, "volatility": null, "paysDividend": false, "raisedDividend": false, "equityRatio": 0.8423, "quadrant": null, "compass": null, "band": "$100M-1B", "cashPctInClass": 77, "growthPctInClass": 98, "source": "SEC XBRL frames, the company’s own audited figures; quadrant split at the median of its size class" }, "harbor": { "signs": [ { "key": "warning", "text": "filed auditor change in the last 12 months" } ], "rule": "Boat condition = number of warning signs: a serious warning filing in 12 months; liabilities over assets; slow and jumpy; negative operating cash; an 80% revenue range of ±25% or wider.", "level": 1, "name": "Sound ship", "plain": "one warning sign" }, "cashFlow": { "fiscalYearEnd": "2025-12-31", "operating": 45585000, "investing": -186812000, "financing": 97389000, "capitalSpending": 670000, "free": 44915000, "trend": [ { "fiscalYearEnd": "2022-12-31", "operating": -31866000, "free": -35828000 }, { "fiscalYearEnd": "2023-12-31", "operating": -81067000, "free": -82683000 }, { "fiscalYearEnd": "2024-12-31", "operating": -86851000, "free": -87054000 }, { "fiscalYearEnd": "2025-12-31", "operating": 45585000, "free": 44915000 } ], "note": "Annual, as filed in 10-K cash flow statements; negative investing/financing = cash going out (capital spending, buybacks, dividends, debt repaid)." }, "investments": { "fiscalYearEnd": "2025-12-31", "cash": 84220000, "shortTerm": 200450000, "longTerm": 106260000, "equityHoldings": null, "totalAssets": 418434000, "ladder": null, "currentRatio": 5.28, "unrealizedGain": 555000, "unrealizedLoss": 10000, "note": "Balance-sheet cash and investment securities at fiscal year end, as filed; short-term = due or saleable within a year. Insurers and banks hold most of their book here." } }